Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| GRANT12908084 | Other Grant/Funding Number | USDA NIFA |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Houston | OTHER |
| Texas Tech University Health Sciences Center | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this project is to understand the combined effects of fish oil and exercise in obesity-associated inflammation. The investigators hypothesize that fish oil will improve gut bacteria profiles, which will in turn potentiate the benefits of an exercise program and improve energy utilization and reduce inflammation and metabolic risk.
Incidence of obesity continues to increase in the United States and worldwide, making its prevention or reduction a public health priority. Nutrition research that can lead to effective prevention strategies is greatly needed. Inflammation is a major underlying cause for obesity, and it is imperative to understand how anti-inflammatory food sources, such as fish oil, could aid in reducing obesity. Moreover, exercise is effective at reducing systemic inflammation and improving insulin resistance. Both exercise and diet can influence health through changes in the gut microbiome; however, no studies have investigated how together these affect gut microbiome and overall metabolic health. The goal is to understand the combined effects of fish oil and exercise in obesity-associated inflammation. The investigators hypothesize that fish oil will improve gut bacteria profiles, which will in turn potentiate the benefits of an exercise program and improve energy utilization and reduce inflammation and metabolic risk. These studies will provide the foundation for development of novel strategies for obesity, inflammation, dyslipidemia and dysglycemia.
The first aim of this study will focus on determining the combined effects of n-3 PUFA and HIIT on improving metabolic risks such as obesity-related markers of inflammation, dyslipidemia, and insulin resistance.
The investigators will test the hypothesis that n-3 PUFA, in addition to HIIT, will have beneficial effects on energy utilization, as well as obesity-related markers of inflammation, dyslipidemia and insulin resistance.
Aim 2.1: Investigate the influence of n-3 PUFA and HIIT on body weight and composition Aim 2.2: Investigate the influence of n-3 PUFA and HIIT on serum markers associated with obesity Aim 2.3: Investigate influence of n-3 PUFA and HIIT on energy utilization/ markers of insulin resistance
The second aim is to determine the combined effects of n-3 polyunsaturated fatty acids (n-3 PUFA) and high-intensity interval training (HIIT) on improving gut dysbiosis.
The investigators will test the hypothesis that n-3 PUFA supplementation will improve gut microbiota composition and related metabolites, which will result in reduced inflammation and ameliorate the metabolic response to a HIIT exercise intervention in an overweight population.
Aim 1.1: Investigate the influence of n-3 PUFA and exercise on gut microbiota composition
Aim 1.2: Investigate the influence of n-3 PUFA and exercise on microbiota produced metabolites
Participants will be randomly allocated to 1 of 4 treatment groups (n = 120), each balanced for sex, BMI, lipid profile, and dietary intake. The goal is to conduct the study in smaller cohorts, such as 10-15 participants/group (n = 40-60).
Participants will first be allocated to two groups: One group will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) and one group will take placebo (safflower oil, AlaskOmega®, from Organic Technologies Inc.) for 4 weeks of initial supplementation.
Following this, one group from the treatment and one from the placebo group (creating 4 groups: (1) placebo + low-intensity training (LIT); (2) n-3 PUFA + LIT; (3) placebo + HIIT; (4) n-3 PUFA + HIIT) will also participate in a 4 x 4 HIIT exercise (4 intervals for 4 min at 85-95% HRmax with 3min active recovery at 50-70% HRmax) program utilizing cycle ergometers on 3 days/week conducted in the research lab and under investigator supervision for 4 weeks while continuing supplementation.
If not asked to exercise, participants will be instructed to maintain their normal level of physical activity but will participate in a time-matched session of low-intensity training (50% HRmax) on 3 days/week conducted in the research lab and under investigator supervision.
All participants will wear a heart rate monitor (Polar H10) provided by TTU throughout the training (HIIT and LIT) to monitor exertion level.
Capsules will be administered in a double-blind fashion and will be identical in appearance. Participants will visit the clinic to pick up capsules. To ensure compliance, subjects will be reminded via phone (text message or phone call based on participant preference) to take their capsules and counts will be conducted when they come in for study visits.
As with any acute metabolic or physiological improvements, beneficial effects of exercise on bacterial taxa and resultant metabolite production are quickly reversed with detraining. Thus, it is of interest to determine if fish consumption can ameliorate the negative metabolic and gut effects of detraining.
At the end of the 4-week intervention (week 8), participants will cease engaging in HIIT or LIT for a 2-week detraining period. Participants will continue taking their assigned supplements.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo & Flexibility Training (Control) | Placebo Comparator | Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 4 weeks. Participants will continue supplementation and will also engage in low-intensity training (control group) for 30 minutes 3 times/week for 4 weeks. All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will continue supplementation and will cease low-intensity training for a 2 week follow-up period. |
|
| Placebo & High-Intensity Interval Training | Active Comparator | Subjects will take placebo (safflower oil, AlaskOmega®) for an initial supplementation period of 4 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will continue supplementation and cease HIIT training for a 2 week follow-up period. |
|
| n-3 PUFA & Flexibility Training (Control) | Active Comparator | Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 4 weeks. Participants will continue supplementation and will also engage in low-intensity training (control group) for 30 minutes 3 times/week for 4 weeks. All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will continue supplementation and cease low-intensity training for a 2 week follow-up period. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Omega-3 polyunsaturated fatty acid | Dietary Supplement | 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change from Baseline in Serum high-sensitivity C-reactive protein at 4 weeks | Serum high-sensitivity C-reactive protein (hs-CRP; mg/L) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Interleukin (IL)-6 at 4 weeks | Interleukin (IL)-6 (pg/mL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Interleukin (IL)-10 at 4 weeks | Interleukin (IL)-10 (pg/mL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Monocyte chemoattractant protein-1 at 4 weeks | Monocyte chemoattractant protein-1 (MCP-1; pg/mL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Tumor necrosis factor at 4 weeks | Tumor necrosis factor (TNF)-alpha (pg/mL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Total Cholesterol at 4 weeks | Total cholesterol (mg/dL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in High-density lipoprotein (HDL)at 4 weeks | High-density lipoprotein (HDL) (mg/dL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Non-high-density lipoprotein (Non-HDL) at 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change from Baseline in Bacterial Profile at 4 weeks | Fecal Microbial DNA (16s Sequencing) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Serum Acetate Profile at 4 weeks | Serum Acetate (SCFA: gas chromatography analysis) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kembra D Albracht-Schulte, Ph.D | Texas Tech University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Texas Tech Kinesiology Building | Lubbock | Texas | 79406 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| n-3 PUFA & High-Intensity Interval Training | Experimental | Subjects will take 4 grams n-3 PUFA (AlaskOmega®) per day (3000 mg EPA and 1000 mg DHA) for an initial supplementation period of 4 weeks. Participants will continue supplementation and will also engage in a 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max . All exercise sessions will be performed on a stationary bike and conducted under investigator supervision. Participants will continue supplementation and cease low-intensity training for a 2 week follow-up period. |
|
|
| High-Intensity Interval Training | Behavioral | A 4 x 4 high-intensity interval training (HIIT) exercise program 3 days/week for 4 weeks. This will include a 3 min warm up at 15% watt max followed by 4 intervals for 4 min at 65% watt max with 3 min active recovery at 15% watt max. |
|
|
| Safflower oil | Dietary Supplement | 4 grams safflower oil (AlaskOmega®) per day |
|
|
| Low-intensity training | Behavioral | A low-intensity training exercise program 3 days/week for 4 weeks. This will include consistently cycling at 50% HRmax for 30 min. |
|
Non-high-density lipoprotein (Non-HDL) (mg/dL) |
| Post-Supplementation at week 4 |
| Mean Change from Baseline in Low-density lipoprotein (LDL) at 4 weeks | Low-density lipoprotein (LDL) (mg/dL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Very-low-density lipoprotein (VLDL) at 4 weeks | Very-low-density lipoprotein (VLDL) (mg/dL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Triglycerides at 4 weeks | Triglycerides (mg/dL). | Post-Supplementation at week 4 |
| Mean Change from Baseline in Total/HDL cholesterol at 4 weeks | Total/HDL cholesterol (mg/dL) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Fasting blood glucose at 4 weeks | Fasting blood glucose (mg/dL) | Post-supplementation at week 4 |
| Mean Change from Baseline in Insulin at 4 weeks | Insulin (μU/mL) | Post-supplementation at week 4 |
| Mean Change from Baseline in Total Body Fat Percentage at 4 weeks | Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is. | Post-Supplementation at week 4 |
| Mean Change from Baseline in Body Weight at 4 weeks | Body weight (kilograms) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Skeletal Muscle Mass Percentage at 4 weeks | Skeletal Muscle Mass Percentage (%SMM): The percent of the body that is composed of skeletal muscle. Like %BF, this number is relative to total mass. | Post-Supplementation at week 4 |
| Mean Change from Baseline in Serum high-sensitivity C-reactive protein at 8 weeks | Serum high-sensitivity C-reactive protein (hs-CRP; mg/L) | Post-Intervention at week 8 |
| Mean Change from Baseline in Monocyte chemoattractant protein-1 at 8 weeks | Monocyte chemoattractant protein-1 (MCP-1; pg/mL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Interleukin (IL)-6 at 8 weeks | Interleukin (IL)-6 (pg/mL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Interleukin (IL)-10 at 8 weeks | Interleukin (IL)-10 (pg/mL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Tumor necrosis factor (TNF) at 8 weeks | Tumor necrosis factor (TNF)-alpha (pg/mL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Total Cholesterol at 8 weeks | Total Cholesterol (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Baseline in High-density lipoprotein (HDL) at 8 weeks | High-density lipoprotein (HDL) (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Non-high-density lipoprotein (Non-HDL) at 8 weeks | Non-high-density lipoprotein (Non-HDL) (mg/dL) | Post-intervention at week 8 |
| Mean Change from Baseline in Low-density lipoprotein (LDL) at 8 weeks | Low-density lipoprotein (LDL) (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Very-low-density lipoprotein (VLDL) at 8 weeks | Very-low-density lipoprotein (VLDL) (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Triglycerides at 8 weeks | Triglycerides (mg/dL). | Post-Intervention at week 8 |
| Mean Change from Baseline in total/HDL cholesterol at 8 weeks | Total/HDL cholesterol (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Fasting blood glucose at 8 weeks | Fasting blood glucose (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Oral glucose tolerance test (OGTT) at 8 weeks | Oral glucose tolerance test (OGTT). Following ingestion of 75 g oral glucose, blood samples will be drawn every 5-10 minutes for the first 30 minutes then every 30 minutes for the next 90 minutes. | Post-Intervention at week 8 |
| Mean Change from Baseline in Insulin at 8 weeks | Insulin (μU/mL) | Post-Intervention at week 8 |
| Mean Change from Baseline in Body Weight at 8 weeks | Body weight (kilograms) | Post-Intervention at week 8 |
| Mean Change from Baseline in Total Body Fat Percentage at 8 weeks | Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is. | Post-Intervention at week 8 |
| Mean Change from Baseline in Skeletal Muscle Mass Percentage at 8 weeks | Skeletal Muscle Mass Percentage (%SMM): The percent of the body that is composed of skeletal muscle. Like %BF, this number is relative to total mass. | Post-Intervention at week 8 |
| Mean Change from Baseline in Serum high-sensitivity C-reactive protein at 10 weeks | Serum high-sensitivity C-reactive protein (hs-CRP; mg/L) | Post-Detraining at week 10 |
| Mean Change from Baseline in Interleukin (IL)-6 at 10 weeks | Interleukin (IL)-6 (pg/mL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Interleukin (IL)-10 at 10 weeks | Interleukin (IL)-10 (pg/mL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Tumor necrosis factor (TNF) at 10 weeks | Tumor necrosis factor (TNF)-alpha (pg/mL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Monocyte chemoattractant protein-1 at 10 weeks | Monocyte chemoattractant protein-1 (MCP-1; pg/mL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Total Cholesterol at 10 weeks | Total Cholesterol (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Baseline in High-density lipoprotein (HDL) at 10 weeks | High-density lipoprotein (HDL) (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Non-high-density lipoprotein (Non-HDL) at 10 weeks | Non-high-density lipoprotein (Non-HDL) (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Low-density lipoprotein (LDL) at 10 weeks | Low-density lipoprotein (LDL)(mg/dL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Very-low-density lipoprotein (VLDL) at 10 weeks | Very-low-density lipoprotein (VLDL) (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Total/HDL cholesterol at 10 weeks | Total/HDL cholesterol (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Triglycerides at 10 weeks | Triglycerides (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Insulin at 10 weeks | Insulin (μU/mL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Fasting blood glucose at 10 weeks | Fasting blood glucose (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Baseline in Skeletal Muscle Mass Percentage at 10 weeks | Skeletal Muscle Mass Percentage (%SMM): The percent of the body that is composed of skeletal muscle. Like %BF, this number is relative to total mass. | Post-Detraining at week 10 |
| Mean Change from Baseline in Body weight at 10 weeks | Body weight (kilograms) | Post-Detraining at week 10 |
| Mean Change from Baseline in Total Body Fat Percentage at 10 weeks | Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is. | Post-Detraining at week 10 |
| Mean Change from Post-Supplementation in Serum high-sensitivity C-reactive protein at 8 weeks | Serum high-sensitivity C-reactive protein (hs-CRP; mg/L) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Interleukin (IL)-6 at 8 weeks | Interleukin (IL)-6 (pg/mL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Interleukin (IL)-10 at 8 weeks | Interleukin (IL)-10 (pg/mL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Monocyte chemoattractant protein-1 at 8 weeks | Monocyte chemoattractant protein-1 (MCP-1; pg/mL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Tumor necrosis factor (TNF) at 8 weeks | Tumor necrosis factor (TNF)-alpha (pg/mL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Total Cholesterol at 8 weeks | Total Cholesterol (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Total/HDL cholesterol at 8 weeks | Total/HDL cholesterol (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in High-density lipoprotein (HDL) at 8 weeks | High-density lipoprotein (HDL) (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Non-high-density lipoprotein (Non-HDL) at 8 weeks | Non-high-density lipoprotein (Non-HDL) (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Low-density lipoprotein (LDL) at 8 weeks | Low-density lipoprotein (LDL) (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Very-low-density lipoprotein (VLDL) at 8 weeks | Very-low-density lipoprotein (VLDL) (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Triglycerides at 8 weeks | Triglycerides (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Insulin at 8 weeks | Insulin (μU/mL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Fasting blood glucose at 8 weeks | Fasting blood glucose (mg/dL) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Body weight at 8 weeks | Body weight (kilograms) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Total Body Fat Percentage at 8 weeks | Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is. | Post-Intervention at week 8 |
| Mean Change from Post-Intervention in Serum high-sensitivity C-reactive protein at 10 weeks | Serum high-sensitivity C-reactive protein (hs-CRP; mg/L) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Tumor Necrosis Factor (TNF) at 10 weeks | Tumor necrosis factor (TNF)-alpha (pg/mL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Interleukin (IL)-6 at 10 weeks | Interleukin (IL)-6 (pg/mL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Interleukin (IL)-10 at 10 weeks | Interleukin (IL)-10 (pg/mL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Monocyte Chemoattractant Protein-1 at 10 weeks | Monocyte chemoattractant protein-1 (MCP-1; pg/mL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Total Cholesterol at 10 weeks | Total Cholesterol (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in High-density lipoprotein (HDL) at 10 weeks | High-density lipoprotein (HDL) (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Non-high-density lipoprotein (Non-HDL) at 10 weeks | Non-high-density lipoprotein (Non-HDL) (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Low-density lipoprotein (LDL) at 10 weeks | Low-density lipoprotein (LDL) (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Very-low-density lipoprotein (VLDL) at 10 weeks | Very-low-density lipoprotein (VLDL) (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Total/HDL cholesterol at 10 weeks | Total/HDL cholesterol (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Triglycerides at 10 weeks | Triglycerides (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Insulin at 10 weeks | Insulin (μU/mL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Fasting blood glucose at 10 weeks | Fasting blood glucose (mg/dL) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Body weight at 10 weeks | Body weight (kilograms) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Total Body Fat Percentage at 10 weeks | Total Body Fat Percentage (%BF): The percent of the body that is composed of fat. This will change based on the amount of fat there is as well as the amount of lean mass there is. | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Skeletal Muscle Mass Percentage at 10 weeks | Skeletal Muscle Mass Percentage (%SMM): The percent of the body that is composed of skeletal muscle. Like %BF, this number is relative to total mass. | Post-Detraining at week 10 |
| Post-Supplementation at week 4 |
| Mean Change from Baseline in Fecal acetate Profile at 4 weeks | Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Propionate Profile at 4 weeks | Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Butyrate Profile at 4 weeks | Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Markers of Serum lipopolysaccharides at 4 weeks | Serum lipopolysaccharides (LPS, ng/ml) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Markers of Serum lipopolysaccharides-binding protein at 4 weeks | Serum lipopolysaccharides-binding protein (LBP, pg/ml) | Post-Supplementation at week 4 |
| Mean Change from Baseline in Bacterial Profile at 8 weeks | Fecal Microbial DNA (16s Sequencing) | Post-Intervention at week 8 |
| Mean Change from Baseline in Serum Acetate Profile at 8 weeks | Serum Acetate (SCFA: gas chromatography analysis) | Post-Intervention at week 8 |
| Mean Change from Baseline in Fecal acetate Profile at 8 weeks | Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Intervention at week 8 |
| Mean Change from Baseline in Propionate Profile at 8 weeks | Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Intervention at week 8 |
| Mean Change from Baseline in Butyrate Profile at 8 weeks | Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Intervention at week 8 |
| Mean Change from Baseline in Markers of Serum lipopolysaccharides at 8 weeks | Serum lipopolysaccharides (LPS, ng/ml) | Post-Intervention at week 8 |
| Mean Change from Baseline in Markers of Serum lipopolysaccharides-binding protein at 8 weeks | Serum lipopolysaccharides-binding protein (LBP, pg/ml) | Post-Intervention at week 8 |
| Mean Change from Baseline in Serum Acetate Profile at 10 weeks | Serum Acetate (SCFA: gas chromatography analysis) | Post-Detraining at week 10 |
| Mean Change from Baseline in Fecal acetate Profile at 10 weeks | Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Detraining at week 10 |
| Mean Change from Baseline in Bacterial Profile at 10 weeks | Fecal Microbial DNA (16s Sequencing) | Post-Detraining at week 10 |
| Mean Change from Baseline in Propionate Profile at 10 weeks | Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Detraining at week 10 |
| Mean Change from Baseline in Butyrate Profile at 10 weeks | Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Detraining at week 10 |
| Mean Change from Baseline in Markers of Serum lipopolysaccharides at 10 weeks | Serum lipopolysaccharides (LPS, ng/ml) | Post-Detraining at week 10 |
| Mean Change from Baseline in Markers of Serum lipopolysaccharides-binding protein at 10 weeks | Serum lipopolysaccharides-binding protein (LBP, pg/ml) | Post-Detraining at week 10 |
| Mean Change from Post-Supplementation in Bacterial Profile at 8 weeks | Fecal Microbial DNA (16s Sequencing) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Serum Acetate Profile at 8 weeks | Serum Acetate (SCFA: gas chromatography analysis) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Fecal acetate Profile at 8 weeks | Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Propionate Profile at 8 weeks | Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Butyrate Profile at 8 weeks | Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Markers of Serum lipopolysaccharides at 8 weeks | Serum lipopolysaccharides (LPS, ng/ml) | Post-Intervention at week 8 |
| Mean Change from Post-Supplementation in Markers of Serum lipopolysaccharides-binding protein at 8 weeks | Serum lipopolysaccharides-binding protein (LBP, pg/ml) | Post-Intervention at week 8 |
| Mean Change from Post-Intervention in Bacterial Profile at 10 weeks | Fecal Microbial DNA (16s Sequencing) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Serum Acetate Profile at 10 weeks | Serum Acetate (SCFA: gas chromatography analysis) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Fecal acetate Profile at 10 weeks | Fecal acetate (SCFA: in fecal samples by liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Propionate Profile at 10 weeks | Propionate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Butyrate Profile at 10 weeks | Butyrate (liquid chromatography tandem mass spectrometry (LC-MS/MS)) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Markers of Serum lipopolysaccharides at 10 weeks | Serum lipopolysaccharides (LPS, ng/ml) | Post-Detraining at week 10 |
| Mean Change from Post-Intervention in Markers of Serum lipopolysaccharides-binding protein at 10 weeks | Serum lipopolysaccharides-binding protein (LBP, pg/ml) | Post-Detraining at week 10 |
| ID | Term |
|---|---|
| D009765 | Obesity |
| D007249 | Inflammation |
| D007333 | Insulin Resistance |
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010335 | Pathologic Processes |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D052439 | Lipid Metabolism Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D004281 | Docosahexaenoic Acids |
| D000072696 | High-Intensity Interval Training |
| D012450 | Safflower Oil |
| ID | Term |
|---|---|
| D015525 | Fatty Acids, Omega-3 |
| D004042 | Dietary Fats, Unsaturated |
| D004041 | Dietary Fats |
| D005223 | Fats |
| D008055 | Lipids |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D005395 | Fish Oils |
| D009821 | Oils |
| D064797 | Physical Conditioning, Human |
| D015444 | Exercise |
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
| D005224 | Fats, Unsaturated |
| D010938 | Plant Oils |
| D028321 | Plant Preparations |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
Not provided
Not provided